Gene mutation, clinical characteristics and pathology in resectable lung adenocarcinoma.

Objective: With the wide use of CT scan in clinical practice, more lung cancer was diagnosed in resectable stage. Pathological examination and genetic testing have become a routine procedure for lung adenocarcinoma following radical resection. This study analyzed special pathological components and gene mutations to explore their relationship with clinical characteristics and overall survival.

Anatomical characteristics of superior and pulmonary subsuperior segment in right lower lobe based on three-dimensional reconstruction.

Objective: Segmentectomy has been widely performed in clinical practice, which required a comprehensive understanding of anatomical structure. In right lower lobe, studies of superior segment (S) were relatively small-sized. And only one study focusing on subsuperior segment (S∗) was published, which showed different results with previous ones.

Immunometabolism: a new dimension in immunotherapy resistance.

Immune checkpoint inhibitors (ICIs) have demonstrated unparalleled clinical responses and revolutionized the paradigm of tumor treatment, while substantial patients remain unresponsive or develop resistance to ICIs as a single agent, which is traceable to cellular metabolic dysfunction. Although dysregulated metabolism has long been adjudged as a hallmark of tumor, it is now increasingly accepted that metabolic reprogramming is not exclusive to tumor cells but is also characteristic of immunocytes. Correspondingly, people used to pay more attention to the effect of tumor cell metabolism on immunocytes, but in practice immunocytes interact intimately with their own metabolic function in a way that has never been realized before during their activation and differentiation, which opens up a whole new frontier called immunometabolism.

Tertiary Lymphoid Structures: A Potential Biomarker for Anti-Cancer Therapy.

A tertiary lymphoid structure (TLS) is a special component in the immune microenvironment that is mainly composed of tumor-infiltrating lymphocytes (TILs), including T cells, B cells, DC cells, and high endothelial venules (HEVs). For cancer patients, evaluation of the immune microenvironment has a predictive effect on tumor biological behavior, treatment methods, and prognosis. As a result, TLSs have begun to attract the attention of researchers as a new potential biomarker.

Opportunities and challenges of neoadjuvant targeted therapy in nonsmall cell lung cancer.

Purpose Of Review: The aim of this study is to summarize the completed and ongoing clinical trials of neoadjuvant targeted therapy, discuss tolerability and efficacy, and explain the role of neoadjuvant targeted therapy in patients with resectable nonsmall cell lung cancer (NSCLC). At the same time, the existing challenges are presented, including assessment methods, biomarkers, surrogate endpoints and so on. We also put forward our views on possible ways to make improvements and establish neoadjuvant therapy a standard treatment in resectable NSCLC.

Adjuvant EGFR tyrosine kinase inhibitors for patients with resected -mutated non-small-cell lung cancer: a network meta-analysis.

To investigate the efficacy and safety of adjuvant EGFR tyrosine kinase inhibitors for resected -mutated non-small-cell lung cancer. Eligible phase II/III randomized controlled trials were included for the network meta-analyses (PROSPERO CRD42021275150). Nine records and 831 patients were involved.